2/18
08:13 am
trda
Entrada Therapeutics (NASDAQ:TRDA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
Medium
Report
Entrada Therapeutics (NASDAQ:TRDA) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.
2/13
06:29 am
trda
Entrada Therapeutics (NASDAQ:TRDA) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
High
Report
Entrada Therapeutics (NASDAQ:TRDA) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
2/13
06:29 am
trda
Entrada Therapeutics (NASDAQ:TRDA) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
High
Report
Entrada Therapeutics (NASDAQ:TRDA) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
2/11
09:48 am
trda
Rating for TRDA
Medium
Report
Rating for TRDA
2/11
09:48 am
trda
Rating for TRDA
Medium
Report
Rating for TRDA
2/11
06:08 am
trda
Entrada Therapeutics initiated with a Buy at Guggenheim
Low
Report
Entrada Therapeutics initiated with a Buy at Guggenheim
2/11
06:08 am
trda
Entrada Therapeutics initiated with a Buy at Guggenheim
Low
Report
Entrada Therapeutics initiated with a Buy at Guggenheim
2/10
04:19 pm
trda
Entrada Therapeutics initiated with a Buy at Guggenheim
Low
Report
Entrada Therapeutics initiated with a Buy at Guggenheim
2/10
04:19 pm
trda
Entrada Therapeutics initiated with a Buy at Guggenheim
Low
Report
Entrada Therapeutics initiated with a Buy at Guggenheim
1/28
08:00 am
trda
Entrada Therapeutics (NASDAQ:TRDA) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $21.00 price target on the stock.
Low
Report
Entrada Therapeutics (NASDAQ:TRDA) is now covered by analysts at Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $21.00 price target on the stock.
1/28
07:34 am
trda
Entrada Therapeutics initiated with an Outperform at Oppenheimer
Low
Report
Entrada Therapeutics initiated with an Outperform at Oppenheimer
1/28
07:34 am
trda
Entrada Therapeutics initiated with an Outperform at Oppenheimer
Low
Report
Entrada Therapeutics initiated with an Outperform at Oppenheimer